Chemomab Therapeutics Ltd - American Depositary Shares — Rendiconto Finanziario (NASDAQ:CMMB) | MetaTrader

Apri il grafico completo

Notizie

Chemomab’s nebokitug shows disease-modifying potential in PSC trial

Chemomab riporta dati positivi a 48 settimane per il farmaco PSC nebokitug

Chemomab reports positive 48-week data for PSC drug nebokitug

ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition

Best Momentum Stocks to Buy for Oct. 23

New Strong Buy Stocks for Oct. 23: MQ, GES and More

SNY's Efdoralprin Alfa Meets Key Endpoints in Rare Disease Study

Roche's Gazyva Secures FDA Nod for Label Expansion in Lupus Nephritis

NVO's Rybelsus Gets FDA Nod to Reduce Heart Risk in Diabetes Patients

ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up

NVO and LLY Stocks Slide as Trump Signals Price Cuts for GLP-1 Drugs

Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in Japan